Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Biofrontera AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 3.61%.
The historical rank and industry rank for Biofrontera AG's ROC (Joel Greenblatt) % or its related term are showing as below:
LTS:0DOL'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1626.56 Med: -110.01 Max: 808.18
Current: -15.41
During the past 13 years, Biofrontera AG's highest ROC (Joel Greenblatt) % was 808.18%. The lowest was -1626.56%. And the median was -110.01%.
LTS:0DOL's ROC (Joel Greenblatt) % is ranked worse than 78.03% of 983
companies
in the Drug Manufacturers industry
Industry Median: 11.46
vs LTS:0DOL: -15.41
Biofrontera AG's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
Biofrontera AG (LTS:0DOL) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Biofrontera AG ROC (Joel Greenblatt) % Related Terms
Biofrontera AG ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Biofrontera AG's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0DOL vs ZTS, UTHR, VTRS: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Biofrontera AG's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biofrontera AG ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biofrontera AG's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Biofrontera AG's ROC (Joel Greenblatt) % falls into.
Biofrontera AG ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 3.61% mean?
Biofrontera AG (LTS:0DOL) has a ROC (Joel Greenblatt) % of 3.61% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Biofrontera AG and its competitors. According to the industry distribution chart, Biofrontera AG ranks #767 out of 983 companies in the Drug Manufacturers industry, placing it in the top 78%.
Is Biofrontera AG's ROC (Joel Greenblatt) % too high?
Biofrontera AG's current ROC (Joel Greenblatt) % is 3.61%. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.46. Biofrontera AG's value of 3.61% is 68.5% below this industry median. Based on the distribution chart, Biofrontera AG ranks #767 out of 983 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Biofrontera AG has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.
How does Biofrontera AG's ROC (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Biofrontera AG ranks #767 out of 983 companies for ROC (Joel Greenblatt) %. This places Biofrontera AG in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 11.46. Biofrontera AG's value of 3.61% is 68.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.46, based on 983 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biofrontera AG's current ROC (Joel Greenblatt) % of 3.61% is 68.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Biofrontera AG and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biofrontera AG's current ROC (Joel Greenblatt) % is 3.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofrontera AG stock overvalued right now?
Biofrontera AG (LTS:0DOL) has a current ROC (Joel Greenblatt) % of 3.61%. The stock's GF Value™ is €2.41, compared to a current price of €2.27 — trading 5.8% below its estimated fair value. The current ROC (Joel Greenblatt) % is 3.61% and 68.5% below the Drug Manufacturers industry median of 11.46. Biofrontera AG's overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Biofrontera AG (LTS:0DOL), the current ROC (Joel Greenblatt) % is 3.61% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biofrontera AG (LTS:0DOL) Overvalued in 2026?
Based on GuruFocus' analysis, Biofrontera AG stock appears to be undervalued.
The current stock price of €2.27 is trading 5.8% below its estimated GF Value™ of €2.41.
Key valuation signals for LTS:0DOL:
ROC (Joel Greenblatt) %: 3.61%
GF Value™: €2.41 vs. price of €2.27 (5.8% below fair value)
Industry Position: 68.5% below the Drug Manufacturers median (#767 of 983)
No single metric tells the full story. See the LTS:0DOL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED and BF-RhodoLED XL, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin. Geographically, the company generates maximum revenue from Germany, and the rest from Spain, the United Kingdom, the rest of Europe, and other regions.
63GF Score
Get the complete analysis for LTS:0DOL
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0DOL has been successfully added to your 
